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Abstract
Osteoradionecrosis (ORN) of the jaw is a late and major complication of radiation therapy for head and neck
cancers. The pathogenesis of ORN is yet to be fully clarified, which has put limitations on effective prevention
and treatment of this condition. Radiation induced tissue hypoxia has been associated with development of
ORN based on the previously proposed ‘hypoxia-hypocellularhypovascular’ theory of ORN pathophysiology.
This indicates that radiation cycles during head and neck cancer therapy cause sustained hypoxia leading to
death of bone cells. Therefore, we hypothesized that severe hypoxia tested at 0.1% oxygen tension alters
plasticity of jaw mesenchymal stem cells, the essential osteoprogenitors vital for bone healing.
We assessed the effect of severe hypoxia (0.1% oxygen) on responsiveness of human orofacial mesenchymal
stem cells (hOFMSCs) isolated from the jaw based on post-hypoxic survival and in vitro/in vivo multilineage
differentiation of surviving cells. The effects of hypoxia inducible factor-1 alpha (HIF-1α) and Endoplasmic
reticulum stress response (ERSR) signaling pathways on activation of vascular endothelial growth factor
(VEGF) by OFMSCs in response to severe hypoxia were also assessed.
We found that OFMSCs succumbed to severe hypoxia because hypoxia depleted osteoprogenitor pools of
OFMSCs. However residual surviving OFMSCs retained appreciable multilineage differentiation capacity.
We also found that activation of both HIF-1α and ERSR signaling pathways in response to severe hypoxia
coregulate downstream activation of VEGF to support recovery actions of residual OFMSCs from severe
hypoxia. These results indicate that hypoxia plays a role in the pathogenesis of ORN and that resilience of
OFMSCs to severe hypoxia can be further explored for tissue regeneration in irradiated jaw bone.
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ABSTRACT 
MODULATORY ROLE OF HYPOXIA IN OROFACIAL MESENCHYMAL STEM 
CELL PLASTICITY 
Temitope T. Omolehinwa (nee Odukoya) 
Sunday O. Akintoye 
Osteoradionecrosis (ORN) of the jaw is a late and major complication of radiation 
therapy for head and neck cancers. The pathogenesis of ORN is yet to be fully 
clarified, which has put limitations on effective prevention and treatment of this 
condition. Radiation induced tissue hypoxia has been associated with 
development of ORN based on the previously proposed ‘hypoxia-hypocellular-
hypovascular’ theory of ORN pathophysiology. This indicates that radiation cycles 
during head and neck cancer therapy cause sustained hypoxia leading to death of 
bone cells. Therefore, we hypothesized that severe hypoxia tested at 0.1% oxygen 
tension alters plasticity of jaw mesenchymal stem cells, the essential 
osteoprogenitors vital for bone healing.  
We assessed the effect of severe hypoxia (0.1% oxygen) on responsiveness of 
human orofacial mesenchymal stem cells (hOFMSCs) isolated from the jaw  based 
on  post-hypoxic survival and in vitro/in vivo multilineage differentiation of surviving 
cells. The effects of hypoxia inducible factor-1 alpha (HIF-1α) and Endoplasmic 
reticulum stress response (ERSR) signaling pathways on activation of vascular 
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endothelial growth factor (VEGF) by OFMSCs in response to severe hypoxia were 
also assessed.  
We found that OFMSCs succumbed to severe hypoxia because hypoxia depleted 
osteoprogenitor pools of OFMSCs. However residual surviving OFMSCs retained 
appreciable multilineage differentiation capacity. We also found that activation of 
both HIF-1α and ERSR signaling pathways in response to severe hypoxia co-
regulate downstream activation of VEGF to support recovery actions of residual 
OFMSCs from severe hypoxia. These results indicate that hypoxia plays a role in 
the pathogenesis of ORN and that resilience of OFMSCs to severe hypoxia can 
be further explored for tissue regeneration in irradiated jaw bone. 
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CHAPTER ONE  
1.0 INTRODUCTION 
Head and neck cancers rank 6th among the top ten common neoplasms (Allegra,E. 2012;  
Graziano,A. 2008). They have a prevalence of 3 - 5.5% in the United States of America 
(USA) (Dandekar, Mitali 2017; Argiris, A. 2003) and 10% worldwide (Argiris, A. 2003). 
Head and neck cancers can affect the hypopharynx, nasopharynx, oropharynx (which 
involves the lingual and palatine tonsils), larynx, oral cavity (including the tongue and 
salivary glands), the paranasal sinuses and the nasal cavity (Figure 1) (Marur, S. 2016;  
Argiris,A. 2008).  
Although neoplasms in the head and neck can develop in the hard or soft tissues 
(Purgina,Bibianna 2017), carcinomas of squamous cell origin are the most prevalent 
(Argiris, A. 2008). They make up 90% of all head and neck cancers (Marur, Shanthi 2008) 
while the incidence of sarcomas in the body is less than 1% (Sturgis, E.M. 2003). Of this 
1%, 5-15% occur in the head and neck region (Sturgis, E.M. 2003).  
Several risk factors have been associated with squamous cell cancers of the head and 
neck. These include smoking, alcohol consumption, chewing of betel quid/areca nut, 
human papilloma virus (HPV), Epstein Barr virus (EBV), smokeless tobacco, cigar 
smoking and marijuana (Argiris, A. 2003; Marur, S. 2016). 
Squamous cell carcinoma of the head and neck region has a predilection for Caucasian 
males of approximately 60 years of age. Due to the increasing smoking habits of females, 
the incidence in females is on the increase (Argiris, A. 2003; Argiris 2008). Interestingly, 
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the non-smoking population of Caucasian males is associated more with HPV-positive 
head and neck cancer.  
About 50-60% of all cases of head and neck cancers are diagnosed at an advanced stage 
of the disease (Marur, S. 2016,  Guizard, A.N. 2017), which has a high impact on the 
outcomes of therapy. 
 
 
 
Management of head and neck cancers is based on several treatment approaches. 
Unfortunately, recurrence occurs in about 10% of patients due to the activity of cancer 
stem cells (CSC) (Allegra, E. 2012; Graziano, A. 2008).  Early diagnosis with prompt 
commencement of treatment is vital to reducing morbidity and mortality.  
 
 
Figure 1. Sites of head and neck cancer 
(www.cancer.gov/types/head-and-neck/head-neck-fact-sheet) 
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1.1 TREATMENT OF HEAD AND NECK NEOPLASMS 
 
There are several treatment modalities for management of head and neck cancers based 
on the site and stage of the primary tumor (Marur, S. 2016). Typically, early-stage head 
and neck cancers are treated with surgery or radiation therapy. Advanced stages 
however, are often treated with combination of both therapies. In addition to surgery and 
radiotherapy, other treatment methods include: chemotherapy (Marur, S. 2016; Marur, 
Shanthi 2008) and immunotherapy/biologic agents (Ye, X. 2017; Moreira, J. 2017). 
 
Surgery 
Surgical options include use of lasers, robotic surgery for resectable tumors or 
conventional open surgery (Marur, S. 2016). What is most important is that the tumor 
margin following surgery should be free of tumor tissues to avoid recurrence.  
 
Radiation therapy 
Radiation doses of 50-70 Gy is often used to treat head and neck cancers (Marur, S. 
2016).  
Radiation therapy can be used alone or in combination with other treatment modalities. 
About 0.9-35% of patients with head and neck cancer receive radiation therapy either as 
the main treatment or as an adjunct therapy (McCaul, James Anthony 2014; Cheriex, 
K.C. 2013). Conventional radiotherapy or intensity modulated radiation therapy are the 
main treatment options in this group of patients.  For non-surgically resectable tumors, a 
combination of surgery and radiation and/or chemoradiotherapy is employed.  
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Chemotherapy and Immunotherapy (Systemic treatment) 
Chemotherapeutic agents like cisplastin, 5-fluorouracil have been in use for several years 
to treat head and neck cancer.  Combination of radiation with chemotherapy 
(chemoradiation) is highly effective in the management of locally advanced head and 
neck cancers, (Jeremic, Branislav 2000; Blasco, Michael A. 2017). 
An Immunotherapeutic agent - cetuximab (a monoclonal antibody that targets epidermal 
growth factor receptors) has also been used successfully. This was the first 
chemotherapeutic agent to be approved by the Food and Drug Administration (FDA) after 
thirty (30) years of wide acceptance and use of cisplastin and 5-fluorouracil (Blasco, 
Michael A. 2017). Success has been reported with using cetuximab either as lone therapy 
or in combination with radiation therapy in treatment of patients with head and neck 
cancer (Bonner, J.A. 2006). Other immunotherapeutic medications used in head and neck 
cancer are monoclonal antibodies that target programmed cell death/apoptosis. 
Examples are pembrolizumab and nivolumab. They are especially used in the treatment 
of recalcitrant, recurring or metastatic head and neck cancers (Blasco, Michael A. 2017).  
 
Stem cell transplant 
Stem cell transplant is a more established treatment for hematopoietic cancers like 
leukemia and lymphoma. In recent years, stem cell transplant has been used successfully 
to treat non-hematopoietic diseases. Animal studies in pigs have been carried out, using 
an osteoradionecrosis model. Successful outcomes have been reported with 
transplantation of autologous bone marrow stem cells into osteoradionecrotic bony 
defects in the jaw (mandible) with noted vascular and bony regeneration (Xu, Junji 2012). 
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In the above study, harvested and expanded iliac crest MSCs were transplanted to the 
jaw of the pig. Another clinical study in Spain, has also reported similar success in a 
clinical trial. A cocktail of autologous mesenchymal stem cell, platelet-rich plasma, non-
platelet-rich plasma and tricalcium phosphate hydroxyapatite scaffold was transplanted 
successfully into a bony defect in a patient with advanced osteoradionecrosis. 
Interestingly stem cells in this study was also from non -jaw site (Mendonca, Jose J. 
2010). A major concern of stem cell therapy is graft rejection and graft versus host 
disease.  
 
1.2 COMPLICATIONS OF THERAPY 
	
Despite the successful outcomes of these therapies, patients with head and neck cancer 
still experience mild to severe treatment complications some of which can be debilitating. 
Some of these complications occur early, while others present late. Patients presenting 
with co-morbid conditions can also further complicate these management complications 
Early complications of head and neck cancer therapy include dysgeusia, chemotherapy 
and radiation-induced mucositis (which largely affects the ability of the patient to have 
proper nutrition) and stomatitis; radiation induced xerostomia and trismus. The 
xerostomia can be transient when the damage to the salivary gland tissue is transient or 
severe due to irreversible damage to the salivary glands. The common late complication 
of head and neck cancer therapy are radiation induced caries and osteoradionecrosis 
(Omolehinwa, T.T. 2016; Rayatt, S. 2007).  However, hypothyroidism can result from 
radiation damage to the thyroid gland and dysphagia can result from damage to the 
pharyngeal constrictor muscles. 
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1.4 OSTEORADIONECROSIS 
Osteoradionecrosis (ORN) is defined as exposed non-healing necrotic bone, for at least 
three (3) months in a previously irradiated field, usually with surrounding compromised 
soft tissue.(Rayatt, S. 2007), in the absence of a recurring, residual or new primary tumor 
(Madrid,C. 2010;  McCaul, James Anthony 2014). 
Osteoradionecrosis can occur in any bone in the irradiation field. The incidence is 
reported to be higher in the jaw bone, with an incidence of 10% among head and neck 
cancer patients and less than 1% in patients with cancer in non-head and neck sites 
(Delanian, Sylvie 2011). ORN of the jaws is a major, usually late complication of head 
and neck cancer radiotherapy (Teng,M.S. 2005; Chrcanovic,B.R. 2010). It occurs in 1-
37% of patients (Gal, T.J. 2000; Rayatt, S. 2007; Sciubba, J.J. 2006).  
A patient receiving radiation dose greater than 50Gy is at a high risk of developing 
osteoradionecrosis (Rayatt, S. 2007). Other risk factors for osteoradionecrosis in a head 
and neck cancer patient receiving radiotherapy include poor oral hygiene, pulpal 
infections, periodontal diseases, old age with co-morbid conditions such as diabetes, and 
procedures such as dental extractions and other intraoral surgical procedures carried out 
before and after radiation (Madrid,C. 2010; Rayatt, S. 2007). 
 
1.4.1 Pathogenesis of osteoradionecrosis 
Several theories have been proposed regarding ORN pathogenesis. A widely-accepted 
theory is development of radiation-induced hypoxic-hypocellular-hypovascular 
environment (3H) in the irradiated bone leading to ORN. (Delanian, S. 2004;  Marx, Robert 
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E. 1983). The 3H theory is based on the premise that radiation damages bone cells and 
blood vessels to induce a hypoxic environment within the bone. This led to the use of 
hyperbaric oxygen (HBO) therapy for the management of ORN (Marx, Robert E. 1983). 
However, HBO therapy has unpredictable clinical outcomes (Shaw, Richard J. 2011).   
Another recent theory is the fibroatrophic theory, which attributes osteoradionecrosis to 
the initiation and dysregulation of fibroblastic processes. The result of this is tissue 
atrophy and subsequently necrosis. A combination of endothelial dysfunction, 
inflammation, microvascular thrombosis and production of free radical from reactive 
oxygen species are implicated (Madrid, C. 2010). The treatment of choice that was 
proposed based on this theory is 800 – 1200 mg daily pentoxifylline and 1000U of α-
tocopherol (McCaul, James Anthony 2014). Pentoxifylline is a vascular dilator which 
increases endothelial flexibility and increased blood flow, leading to increased 
vascularization. Pentoxifylline also has anti-tumor necrosis factor alpha (anti-TNFα) effect 
which decreases the inflammatory cytokine cascade at the irradiated site. Alpha 
tocopherol also known as Vitamin E, is an antioxidant. It scavenges free oxygen radicals 
therefore mopping up the reactive oxygen species formed by vascular damage and 
hypoxia. A combination of Pentoxifylline, alpha tocopherol and clodronate (an 
aminobisphosphonate drug) has been shown to be effective in resolving soft tissue 
fibrosis induced by radiation damage and effects of osteoradionecrosis. (Delanian, Sylvie 
2011). 
 
1.4.2 Role of stem cells in the pathogenesis of ORN 
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Based on Robert Marx’s 3H theory (Marx, Robert E. 1983), radiation causes vascular 
damage (hypovascularity) which translates to reduced oxygen tensions in the affected 
tissues.  The combination of hypovascularity and hypoxia activate release of reactive 
oxygen species causing more vascular damage and increased hypoxia. This continuous 
cycle of hypoxia and hypovascularity cause cellular death (hypocellularity) (Figure 2). The 
undifferentiated progenitor cells are believed to be affected by this radiation and hypoxic 
insult.  
 
 
 
 
 
 
1.5 DIAGNOSIS AND STAGING OF JAW OSTEORADIONECROSIS 
Jaw osteoradionecrosis is diagnosed based on clinical and radiographic presentation in 
a patient who presents with a previous history of head and neck radiation therapy. Patient 
Figure 2.  Relationship between radiation, hypovascularity, hypoxia and 
hypocellularity 
	
Hypocellularity 
Hypoxia
aaa 
ROS 
hypovascularity 
MSCs Pre-osteoblast Osteoblast 
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may be asymptomatic with only findings on radiographic examination or other imaging 
studies. Patients can also present with pain, infections, orocutaneous fistula, bony 
sequestrum, compromised soft tissue, trismus and pathologic fractures.  
 
Stage Length of affected 
bone/ Associated 
structures 
(damaged/exposed) 
Presence/absence of 
symptoms  
Treatment 
1 <2.5 cm Asymptomatic Improve oral hygiene 
and medication only. 
2 >2.5 cm Asymptomatic with 
pathologic fracture and/or 
inferior alveolar nerve (IAN) 
involvement 
Medication treatment 
only; except for 
presence of dental 
sepsis and 
loose/necrotic bone. 
3 >2.5 cm Symptomatic. No other 
features of bone necrosis, 
but presence of persistent 
symptoms despite 
medication treatment 
Debridement of 
loose/necrotic bone. 
Local pedicle flap 
4 > 2.5cm Symptomatic. Pathologic 
fracture with IAN 
involvement and/or 
orocutaneous fistula 
Reconstruction with 
free flap, if patient’s 
overall health allows 
 
 
 
Different attempts have been made to classify osteoradionecrosis. One of the more recent 
classifications is based on the extent of the necrotic bone damage, presence or absent 
of symptoms and the treatment modality (Table 1) (Lyons, Andrew 2014; 
Omolehinwa,Temitope T. 2016). Stage 1 of this classification can be interpreted to include 
intact soft tissue clinically, but with radiographic findings of damaged bone. 
Table 1. Adapted from Omolehinwa,T.T. 2016; Lyons, Andrew 2014	
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1.6 MANAGEMENT OF OSTEORADIONECROSIS 
Management range from improving oral hygiene, symptom control with use of analgesics 
and antibiotics, debriding, sequestrectomy, radical resection, hyperbaric oxygen and 
pharmacologic agents e.g. Pentoxifylline, alpha tocopherol and clodronate. 
 
1.7 STEM CELLS 
Stem cells are cells that have the potential to proliferate, and ability to self-renew and 
differentiate into multiple cell types. Stem cells can be embryonic, fetal or adult/post-natal 
in origin (Table 2) (Shanti, Rabie M. 2007).  
 
Types of stem cells 
Embryonic stem cells are pluripotent in nature i.e. they are capable of infinitely 
proliferating. This includes proliferation to form trophoblasts, ectoderm, mesoderm and 
endoderm of epithelial origin. They can also remain undifferentiated by not committing to 
any specific lineage (Ulrich, Henning 2017; Shanti, Rabie M. 2007; Thomson,J A. 1998). 
Embryonic stem cells arise from the inner cell mass of a developing blastocyst. Although 
embryonic stem cells are ideal for tissue regeneration, their use has been limited by 
ethical issues (Lo, B. 2009). 
 
Fetal stem cells are capable of extensive proliferation and differentiation and can be 
isolated from developing fetal organs (Olivier, Valerie 2004). They are also pluripotent in 
nature ( Lo, B. 2009). 
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Adult stem cells on the other hand are multipotent. They can differentiate into many but 
still limited cell types. Post-natal stem cells include hematopoietic (from endoderm), 
mesenchymal (from mesoderm) and epithelial (from ectoderm) stem cells (Table 3) 
(Shanti, Rabie M. 2007). Bone marrow MSCs are post-natal stem cells isolated from the 
bone marrow. They have the multilineage properties of adult MSCs and can readily 
commit to the osteogenic lineage (Yosupov, N. 2017). 
 
Stem Cell Source  Characteristic  
Embryonic Inner mass blastocyst Pluripotent, unlimited proliferation 
Fetal Developing organ (e.g. aborted fetus) 
Pluripotent, unlimited 
proliferation and differentiation 
Adult/Post- natal 
From mesoderm, 
endodermal and 
ectodermal origins 
Multipotent 
Induced Pluripotent 
stem cell Re-engineered Adult MSC Pluripotent 
 
	
	
Induced pluripotent stem cells are reengineered somatic postnatal stem cells. They 
have been reprogrammed with genetic materials from viruses or plasmids vectors to 
regain the characteristics of embryonic stem cells (Ulrich, Henning 2017; Lo, B. 2009).  
 
Table 2. Types of stem cells Omolehinwa 2017 	
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Stem Cell Source Tissue (Location) Differentiation Potential 
Hematopoietic Bone marrow Blood, endothelial, myoblast, and hepatic (oval) cells 
Epithelial Epidermis, gut All cells of epithelium crypts, and all cells of epidermal cells 
Mesenchymal 
Bone marrow, muscle, 
trabecular bone, adipose 
tissue, dermis, 
periosteum, blood, 
synovial membrane, 
periodontal ligament, 
and deciduous teeth 
Adipocyte, chondrocyte, 
myoblast, osteoblast, 
cardiomyocyte, hepatocytes, 
neuron, astrocyte, 
endothelial, fibroblast, and 
stromal cells 
	
	
	
 
Another unique group of stem cells are cancer stem cells. They are stem cells with genetic 
aberrations, leading to continuous cell proliferation with no signals to turn off the growth 
of the cells. This leads to tumorigenesis. 
This literature review focuses on mesenchymal stem cells (MSCs). This is because MSCs 
are progenitors of osteoblasts and are implicated in osteoradionecrosis.  
 
Table 3. Adult stem cells adapted from Shanti, Rabie M. 2007 
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1.8 MESENCHYMAL STEM CELLS 
Mesenchymal stem cells (MSCs) are unique population of postnatal (adult) stem cells. 
They have the potential to self-renew and differentiate into various cell lineages 
(multipotency) and tissues that include bone, cartilage, muscle and fat (Shanti, Rabie M. 
2007; Oh,M. 2015; Sacchetti, Benedetto 2007). MSCs were first isolated from the bone 
marrow and described by Friendenstein (Friedenstein, A.J. 1976). Apart from the bone 
marrow, MSCs have also been successfully isolated from the brain, liver, umbilical cord, 
chorionic villi, Wharton’s jelly, fetal tissue, placenta, menstrual blood, dental pulp tissue, 
skin, muscle, heart, gingival tissue and bone marrow. (Zhang, W.X. October 2006; 
Gronthos, M. 2000; Ejtehadifar, M. 2015; Madrigal, M. 2014).  
Since bone marrow is the most common donor site for isolation of MSCs, (Minguell, J.J. 
2001; Levy, Débora), this project will focus on bone marrow MSCs and potential 
application for bone repair/regeneration in osteoradionecrosis of the jaw. 
 
Properties of MSCs 
Based on the position statement the International Society for Cellular therapy in 2006 
(Dominici, M. 2006), the properties of MSCs include:  
1. An ability to express specific surface antigens. These surface antigens include CD105, 
CD73, CD44, CD13 CD90. It is however important to note that MSCs do not express the 
following markers CD45, CD 79α, CD19, CD14, CD34, CD 11b and HLA-DR surface 
molecules (Table 4) (Ejtehadifar, M. 2015;  Dominici,M. 2006). 
2. Ability to adhere to plastic surfaces when expanded in vitro, while ensuring adherence 
to standard culture protocols. 
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3. Must show multipotent differentiation ability when expanded in vitro 
4. Should be capable of ex vivo expansion (Dominici, M. 2006). 
MSCs are also known to have immunomodulatory properties. They exert this effect by 
inhibiting the proliferation of T-cell (Lotfinegad, P. 2014). This makes MSCs useful in 
management of autoimmune diseases that require modification of the immune system. 
An example is Graft-versus host disease (GVHD) especially acute GVHD  (Le Blanc, 
Katarina 2005). 
 
 
Characteristics of Mesenchymal Stem Cells 
1 Adherence to plastic in standard culture conditions 
 
2 Phenotype Positive (≥95% + ) Negative (≤2% + ) 
CD105 CD45 
CD73 CD34 
CD90 CD14 or CD11b 
 CD79α or CD19 
 HLA-DR 
 
3 In vitro differentiation: osteoblasts, adipocytes, chondroblasts (demonstrated by 
staining of in vitro cell culture) 
	
	
	
	
	
The unique site-specific properties of bone marrow mesenchymal stem cells  
Previous studies have shown that bone marrow MSCs have unique phenotypic and 
behavioral properties depending on their site of harvest. This was especially noted in 
Table 4. Characteristics of MSCs based of surface markers (Dominici,M. 
2006) 
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MSCs of the orofacial region (especially jaw bones). It was discovered that orofacial 
MSCs have features that differentiate them from MSCs of non-jaw sites.  These properties 
include a higher proliferative capability and delayed senescence (Figure 3), more 
radiosensitivity and higher capacity for in vitro osteogenic and adipogenic differentiation 
(Akintoye,S.O. 2006; Damek-Poprawa,Monika 2010). These differences have been noted 
in MSCs of humans, porcine, canine, mice and rat (Akintoye,S.O. 2006;  Bugueño, Juan 
2017;   Yamaza, T. 2011)  
 
 
 
 
 
The site- specific properties of the jaw MSCs are possibly associated with jaw-specific 
disorders like cherubism, medication related osteonecrosis of the jaw (MRONJ), 
craniofacial fibrous dysplasia and hyperparathyroid jaw tumor syndrome (Akintoye,S.O. 
Figure 3. Skeletal site-specific proliferative capacity of MSCs.  
OFMSCs are significantly more proliferative than non-oral MSCs based on 
proliferation and population doubling properties (Akintoye,S.O. 2006). 
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2006). Additionally, the high proliferative properties of orofacial MSCs can be associated 
with a disproportionate sensitivity to hypoxia and consequent jaw susceptibility to ORN.  
 
Plasticity of mesenchymal stem cells 
The ability to differentiate in a multilineage fashion, regardless of the site/tissue of origin 
is referred to as plasticity (Zhang, W. October 2006; Brazelton, Timothy R. 2000). This 
property of the adult stem cell makes it particularly clinically relevant in the treatment of 
several medical conditions, including but not limited to diseases of the orofacial region 
such as osteonecrosis of the jaw, radiation induced salivary gland damage and Sjögren’s 
syndrome (Catacchio,I. 2013). 
Among the body tissues, the bone marrow MSCs have the highest plasticity, with multiple 
lineage differentiation potential (Ejtehadifar, M. 2015) and a higher prospect for 
osteogenic differentiation ( Cicione, C. 2013; Muraglia, A. 2000).  
The plasticity of the bone marrow MSCs is associated with its oxygen gradient, a hypoxic 
state being required to keep the cell in a quiescent or inactive state (D'Ippolito,G. 2006). 
A lot of studies have been carried out to study the effect of hypoxia on cell plasticity (Jiang 
et al. 2015; D'Ippolito et al. 2006; Cicione et al. 2013; Grayson et al. 2006). However, the 
effects of hypoxia on differentiation capabilities of these cells are still unclear (Cicione et 
al. 2013; Grayson et al. 2006; Holzwarth et al. 2010). The exact knowledge of the 
mechanisms of action of hypoxia on cell plasticity is still under study. 
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Mesenchymal Stem cell niche 
Adult stem cells reside in a specified area within the tissues/organ. This distinct area is 
called the stem cell niche/microenvironment. MSC niche are found in perivascular areas, 
in close proximity to blood vessels. (Farrington-Rock,C. 2004). These cells are spindle 
shaped or fibroblast like (Friedenstein, A.J. 1976; Marquez-Curtis,Leah A. 2015). Within 
the niche, MSCs are quiescent until induced to differentiate and commit to a specific 
lineage by events such as irradiation, bone loss and other types of insults (Figure 4).   
 
 
 
 
 
 
 
 
Figure 4. The Stem cell niche ( Oh, M. 2015) 
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Isolation of Bone Marrow Mesenchymal stem cells 
Although MSCs are only 0.001 – 0.01% of cells within the bone marrow compartment 
(Marquez-Curtis,Leah A. 2015), significant amount of MSCs can still be isolated by plastic 
adherence in a plastic culture dish. It is not practicable to obtain pure MSCs by plastic 
adherence because of the close proximity of MSC niche with the hematopoietic niche and 
other stem cell niches. Therefore, MSCs isolated by plastic adherence usually display 
heterogeneous properties. Each progenitor MSCs proliferates into a clone of 50 or more 
heterogeneous fibroblast-like cells referred to as colony-forming units fibroblastic (CFU-
F). The CFU-F ability of MSC is a mark of stemness and decreases with advancing age 
of the donor.  
The expanded cells must secondly be tested for MSC specific surface antigens as noted 
in Table 4 above, by cell sorting (usually Fluorescence activated cell sorting –FACS). 
Human primary bone marrow mesenchymal stem progenitor cells, in addition to the above 
stated markers (Table 4), have some specific markers exclusive to this group of cells. 
They include STRO-1, CD 146 (also known as MUC 18), SUSD2, CD106, FZD9, CD271 
and LEPR (Li, Hongzhe 2016).  
The media in which the MSCs are cultured is also important. Growth medium 
supplemented with Fetal Bovine Serum (FBS) are essential components of the culture 
medium. 
 
Cryopreservation, Storage and revival of mesenchymal stem cells 
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MSCs have application in tissue engineering. It is important that MSCs can be expanded 
ex vivo and cryopreserved for long term storage. The use of appropriate freezing medium 
and long-term storage in liquid nitrogen chambers have been effective in maintaining 
viability of MSCs. This storage approach slows down MSC metabolic activity while still 
maintaining viability (Marquez-Curtis,Leah A. 2015).  
 
1.9 CANCER STEM CELLS 
Cancer stem cells (CSCs) of the head and neck tumors were first identified in 2007 
(Prince,M.E. 2007). They are believed to be unique/rare stem cells that do not commit to 
any lineage, but continually self-renew in a hap-hazard manner, resulting in tumorigenesis 
(Reya, T. 2001). 
Like all other stem cells, CSCs exist in a niche within the cancer and can be distinguished 
phenotypically by surface markers such as CD44, CD22 and CD133 (Allegra, E. 2012). 
CD44 positive CSCs are especially known to promote cancer resistance to therapy, this 
subset of CSCs is also responsible for the self-renewing property that support the growth 
of solid tumors (Okamoto,A. 2009) 
 
1.10 HYPOXIA 
The fetus develops a respiratory and circulatory system early in-utero because oxygen is 
vital for survival. The inspired oxygen can be effectively circulated to every tissue in the 
body via hemoglobin transport of oxygen in the red blood cells (Semenza, Gregg L. 1998). 
A lack of adequate supply of oxygen is termed hypoxia and can be defined as a shortage 
in the amount of oxygen reaching the tissues. This results in reduced tissue perfusion. 
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Hypoxia typically halts the cell cycle in mammalian cells, with resultant cell death 
(Basciano, L. 2011). The body cells and tissues attempts to counteract changes in oxygen 
tension by activating survival and cellular stress pathways (Buravkova,L.B. 2014). 
Some cells in the body however, have adapted to a hypoxic microenvironment. An 
example is MSCs that have developed the ability to maintain regular cellular activities in 
spite of the hypoxic environment (Buravkova, L.B. 2014). 
One of the major cellular stress/survival pathways activated in response to hypoxia is the 
hypoxia inducible factor 1 (HIF-1) pathway. HIF-1 pathway is essential for the 
maintenance of oxygen homeostasis. This pathway acts by reducing tissue oxygen 
demand while increasing oxygen delivery via vessel dilatation, angiogenesis and 
erythropoiesis (Semenza, Gregg L. 1998). The stability of HIF-1 is crucial in its response 
to tissue hypoxia (Weng and Semenza (2003); Buravkova,L.B. 2014).  
It has been shown in HeLa S3 cell lines that HIF-1 has a short half-life of one minute and 
can be detected in the nucleus within 2 minutes of exposure to 0.02 – 5% oxygen 
concentration. HIF-1 was also shown to reach a maximum level of expression after 1 hour 
of continuous exposure to hypoxia (Jewell, U.R. 2001). 
 
HIF isoforms 
Existing HIF isoforms include HIF-1α, HIF-2α, HIF-3α and HIF-1β. HIF- 1α and HIF-2 α 
are closely related and bind to hypoxic responsive elements (HRE) that activate 
transcriptional target genes. Nonetheless, the target genes of both isoforms are different. 
HIF-2α for example has been shown downstream to activate erythropoietin (EPO) a gene 
important for erythropoiesis. This is the case especially in hepatocytes. On the other 
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hand, HIF- 3α has antagonizing actions against HRE (Ratcliffe, P.J. 2007). HIF-1β is 
essentially involved under hypoxia with HIF-1α and HIF-2α binding to it, under hypoxic 
conditions. 
 
Hypoxia and Mesenchymal stem cells 
Hypoxia in tissues could be physiologic or pathologic in origin. Whether physiologic or 
pathologic, hypoxia causes modifications in cellular responses such as angiogenesis, red 
blood cell formation, as well as cell proliferation and differentiation (Frolova,O. 2012;). 
In MSCs, oxygen gradient is maintained between 1% (Xu,L. 2014; Holzwarth et al. 2010) 
and 12.5% (Heppenstall, Grislis, and Hunt 1975,   Ito, A. 2015). MSCs have adapted to 
this hypoxic state by stabilizing HIF-1α. However, activation of the HIF-1 pathway and 
translocation of HIF-1α subunit into the nucleus occurs after exposure of MSCs to hypoxia 
for a duration that can range from 6 – 72 hours (Buravkova,L.B. 2014). Under physiologic 
hypoxia, MSCs have a higher proliferation capacity and colony forming efficiency. 
(Buravkova,L.B. 2014; Basciano, L. 2011).  
Interestingly, when ex vivo expanded MSCs are subjected to physiologic hypoxic 
conditions (1-12% O2), they are able to retain their stem cell properties with increased 
self-renewal ability and delayed senescence compared to those cultured under normoxic 
conditions. ( Ito, A. 2015}  
The effect of this severe hypoxic state on the ability of the MSC to differentiate from one 
lineage to the other has not been fully clarified. A study by Ito et al observed that MSCs 
are likely to die by apoptosis when exposed to oxygen concentration as low as 0.4% ( Ito, 
A. 2015,  Xu,L. 2014, Ceradini,D.J. 2004). However, Jiang C. et al in 2015 reported that 
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osteogenic differentiation was severely impaired in severe hypoxic state using 0.2% 
oxygen, while adipogenic differentiation was enhanced. (Jiang,C.M. 2015). Both human 
MSCs (hMSCs) and rat MSCs have demonstrated increased osteogenesis and 
suppressed adipogenesis at 2% and 1% oxygen concentrations ( Xu,L. 2014; Wagegg, 
M. 2012; Lennon, D.P. 2001). 
Hypoxia at 1% O2 tension) was reported to diminish chondrogenesis in MSCs obtained 
from the iliac crest of patients undergoing hip replacement (Cicione,C. 2013) while a lot 
more studies reported an increase in chondrogenesis under hypoxia (Kanichai, M. 2008). 
This was supported by elevated expression of SOX9, SOX5, AGC1, COL2A1 and other 
collagen types, SOX6, choindrointin-4 sulphate, aggrecan and glycosaminoglycan 
(Buravkova,L.B. 2013; López, Y. 2013; Buravkova,L.B. 2014). 
Early progenitor MSCs have the innate property of differentiating in a multilineage fashion 
(Catacchio et al 2013). Based on preliminary data from our study, severe hypoxia 
apparently modulates the survival of early MSC progenitors. However, it is unclear if early 
MSC progenitors can recover from the stress of severe hypoxia and commit to lineage 
differentiation. Other previous studies suggest that severe hypoxia alters multilineage 
differentiation pattern of MSCs from non-oral skeletal sites (Cicione et al 2010) but it is 
unclear if this responsiveness to hypoxia is skeletal site-dependent. 
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HIF-1α 
HIF-1α is a transcriptional factor that encodes for the HIF-1α gene and is responsible for 
cellular response to hypoxia (Kanichai et al 2008). It is accepted as the hallmark of 
hypoxia (Oudina et al 2011;Schipani 2005). It has a heterodimeric structure, containing 
two alpha-helix structures, which are connected by a loop (Figure 5). HIF-1 was first 
named in 1992 by Semenza and Wang, when they noted a certain protein that was bound 
to hypoxia only in Hep3B human hepatoma cells (Semenza, G.L. 1992). 
HIF- 1α is present in all tissues (Pal Singh,R. 2012) and transiently present in the cell 
cytoplasm under normoxic conditions. HIF-1α is unstable under normoxia as it is quickly 
degraded. This is achieved by hydroxylation of proline residues and ubiquitination by the 
interaction of the hydroxylation process with von Hippel Lindau tumor suppressor protein 
(Figure 6).  
 
Figure 5. Heterodimeric structure of HIF-1α (Wu, D. 2015) 
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However, under hypoxic conditions, HIF-1α is more stable and translocates into the 
nucleus. It binds with HIF-1β in the nucleus and the coupling of HIF-1α and HIF-1	β binds 
to the hypoxic responsive element at the DNA binding site. This results in the activation 
of downstream target genes like VEGF which is responsible for angiogenesis 
(Weidemann, A. 2008).  
The HIF-1 signaling pathway is activated in regions of physiologic hypoxia (1-1.8%) (Xu, 
L. 2014) such as during chondrocyte differentiation at the embryonic growth plate 
(Schipani 2005). HIF-1α plays a role in maintaining MSCs in an undifferentiated quiescent 
state (Park, I.H. 2013,  Holzwarth,C. 2010), while also maintaining MSC plasticity 
(D'Ippolito,G. 2006).   The role of HIF-1α in cancer biology is well defined, especially with 
hypoxia in tumor cells being responsible for resistance of affected tissues to radiation 
therapy (Meijer, Tineke W.H. 2012) 
Figure 6. Schematic diagram of HIF-1 pathway (Omolehinwa 2017) 
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However, it is unclear if this mechanism is dysregulated under severe hypoxic conditions 
beyond physiologic hypoxia.   
 
Endoplasmic reticulum stress response 
In addition to the HIF-pathway, the endoplasmic reticulum stress response (ERSR) is also 
activated under hypoxic conditions. It is unclear whether HIF and ERSR pathways co-
regulate MSC responsiveness to hypoxia. The rough endoplasmic reticulum is an 
intracellular organelle responsible for protein synthesis. Protein folding also occurs in the 
ER, followed by transport of the folded proteins to the Golgi apparatus. This process of 
folding and transport of protein occurs in the presence of chaperone proteins, which 
ensures that the transported proteins are properly folded. An example of this chaperone 
protein is BiP (Binding immunoglobulin Protein). Under some stressful situations to the 
endoplasmic reticulum, like the presence of viral infections, disruption of normal redox 
reactions, glucose and calcium dysregulation or even the presence of hypoxia; there is 
improper protein folding, which is called unfolded protein response or ER stress response 
(ERSR). Unfolded protein response is regulated by three signaling pathways: Protein 
kinase RNA-like ER kinase (PERK), Activator transcription factor 6 (ATF6); which both 
under physiologic conditions of folded proteins, bind to Bip and keep Bip in an inactive 
form. Bip however becomes activated when many unfolded proteins are present in the 
ER, with resultant dissociation of Bip from ATF6, PERK, and IRE1α. Under ER stress, 
PERK also prevents mRNA translation which prevents the influx of newly produced 
proteins into the already stressed ER. This is accomplished by the phosphorylation of 
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eukaryotic translation Initiation factor 2 (eIF2α). eIF2α activates activator transcription 
factor 4 (ATF4), which downstream results in activation of VEGF. 
The third signaling pathway, Inositol-requiring protein 1α (IRE1α), binds directly to 
unfolded proteins. In a situation where the ER stress response is prolonged with a 
continuous burden of unfolded proteins, cellular dysfunction occurs with resultant cell 
death/apoptosis. IRE1 α is believed to be responsible for activation of apoptosis pathway 
(Sano,Renata 2013) 
 
Endoplasmic Reticulum Stress response and Hypoxia in MSCs 
Since VEGF is a downstream effector of both HIF and ERSR pathways, it is still unclear 
if both pathways co-regulate VEGF-dependent angiogenesis and recovery from hypoxia.  
A study by Li Z in 2010, showed that hypoxia and serum deprivation of MSCs induced 
cell death and activated ER stress response (Li, Zongwei 2010). However, there is still 
paucity of information on the role of HIF-1α and ERSR pathways in recovery of cells from 
hypoxic insult. 
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CHAPTER TWO  
 
2.0 RESEARCH AIMS 
2.1 PURPOSES 
 
The management, especially prevention of osteoradionecrosis till date has not been 
figured out in its entirety.  
The purpose of this study is to determine whether severe hypoxia suppresses 
undifferentiated orofacial mesenchymal stem cell (OFMSC) population and their 
multipotent differentiation capacities.  We will also assess the modulatory roles of 
hypoxia-inducible factor (HIF)-1α and Endoplasmic Reticulum stress response (ERSR) 
signaling in the responsiveness of orofacial MSCs subjected to severe hypoxia. The 
following specific aims will be embarked upon: 
 
2.2 SPECIFIC AIMS 
	
Aim 1: To determine whether severe hypoxia depletes undifferentiated jaw 
mesenchymal stem cells (OFMSCs)  
Hypothesis: Severe hypoxia suppresses OFMSCs  
Rationale: MSCs characteristics are phenotypically and functionally skeletal site-specific 
Approach: MSCs from mandible/maxilla (OFMSCs) were subjected to severe hypoxia 
(0.1% O2) and characterized based on cell surface markers of stemness and survival. 
Iliac crest (ICMSCs) was used as control. 
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Aim 2: To determine whether severe hypoxia modulates OFMSC multilineage 
differentiation  
Hypothesis: Severe hypoxia dysregulates OFMSC multi lineage differentiation 
Rationale:  Post-hypoxic repopulation of early progenitor cells and multilineage 
differentiation are essential for bone recovery and healing  
Approach: Multilineage differentiation capacities of OFMSCs subjected to severe hypoxia 
was assessed based on osteogenesis and adipogenesis, using immunological and 
molecular approaches. 
 
Aim 3: To determine whether OFMSC susceptibility to severe hypoxia is dependent 
on HIF 1 and endoplasmic reticulum stress response (ESRS) signaling pathways 
Hypothesis: Altered HIF and ERSR signaling undermines survival of OFMSC following 
severe hypoxia 
Rationale: HIF 1 alpha and ESRS signaling regulate cellular response to hypoxia and 
cellular stress response respectively. 
Approach: The activities of HIF-1α and ERSR via its PERK arm on OFMSCs subjected 
to hypoxia were assessed. Pharmacological and molecular approaches were used to 
upregulate or downregulate both HIF 1 alpha and ERSR pathways to assess their 
downstream effects on VEGF activation. 
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CHAPTER THREE 
 
3.1 EXPERIMENTAL OUTLINE 
	
	
	
 
 
 
 
 
 
 
	
Figure 7. Study outline 
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3.2 METHODS: 
Sample and Cell culture 
Human mesenchymal stem cells (MSCs) from the jaw (maxilla or mandible) of three 
healthy normal volunteers were selected from previously isolated and cryopreserved 
MSCs in the laboratory of Dr. Akintoye. The maxilla/mandible MSCs termed orofacial 
MSCs (OFMSCs) were comparatively analyzed with Iliac crest MSCs (ICMSCs) of same 
individuals. The ICMSCs served as non-oral control MSCs. 
The primary hMSCs were further expanded in growth medium containing α-modified 
Minimum Essential Medium (α-MEM, Life Technologies, Grand Island NY) supplemented 
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 100 U/ml 
penicillin, 100 mg/ml streptomycin sulfate and 2 mM glutamine (Gibco, Life technologies, 
NY). Expanded cells were maintained in a humidified atmosphere containing 5% CO2 and 
at a temperature of 370C. Twenty-four (24) hours after onset of expansion, MSCs were 
checked for plastic adherence, while non-adherent cells were removed by suction.  After 
a brief rinse of the MSCs with phosphate- buffered solution (PBS), the growth medium 
was replenished. This procedure was repeated every 4 days until 80% cell confluence 
was attained. At this point, cells were detached from flask with 0.5% trypsin (Invitrogen- 
Life Technologies, Carisberg CA) and re-plated for the rest of the experiments as outlined 
below. Early cell passages (between P2 to P4) were used for all experiments.  
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Cryopreservation and thawing of MSCs  
Excess MSCs not immediately used for an experiment were saved in freezing medium, 
made up of growth medium and dimethylsulfoxide (Fisher Scientific, USA) at 1 x106 
cells/ml and cryopreserved in liquid nitrogen for long term storage or -80OF for short term 
storage. 
 
Induction and maintenance of severe hypoxic conditions 
Two Billups-Rothenberg modular hypoxic chamber (California, USA) were used to 
maintain severe hypoxia at 2% and 0.1% oxygen respectively for an initial determination 
of appropriate experimental parameters. The chambers were initially flushed with 2-5 
mmHg pressure of either 2% or 0.1% O2, to eliminate ambient air. This was followed by 
preconditioning of a serum-free growth medium by closing the chamber for 4 minutes at 
a pressure of 4mmHg. Thereafter 10% FBS was added to the pre-conditioned medium 
before being introduced to the MSCs hypoxic treatment group. The hypoxic chambers 
were again flushed with 25mmHg of the different oxygen (O2) tensions for 4 minutes, 
followed by treatment of the cells at a flowrate of 2-5 mmHg for 15 minutes. The hypoxic 
chambers were transferred to a cell culture incubator and maintained under 5% CO2 and 
370C temperature. Early passage OFMSCs (passages 2 to 4) were divided into two 
groups; one group was cultured under normoxic conditions (21% O2, 5% CO2 and 
temperature of 37.50C), while the second group was subjected to severe oxygen tensions 
(0.1% O2, 5% CO2). 
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Selection of optimal hypoxic parameters 
OFMSCs seeded at a density of 9.5 X 104 cells/ml, were treated with 21%, 2% and 0.1% 
O2 as described above.  MSC incubation under hypoxia was performed for 1, 3, 6, 12 and 
24 hours to assess cell survival using trypan blue staining and a hemocytometer. Results 
were normalized to cells treated under 21% oxygen and iliac-crest mesenchymal stem 
cells (ICMSCs) were used as non-jaw site control. The percentage of surviving cells and 
time point of 50% cell survival was also assessed (lethal dose 50 or LD50. Based on these 
outcomes, severe hypoxia of 0.1% O2 and exposure time of 6 hours were selected as 
optimal parameters simulate a severe hypoxic environment.  
 
Phenotypic identification of mesenchymal stem cell and osteoprogenitor surface 
markers 
Characterization of hMSCs surviving severe hypoxia was carried out by 
immunophenotyping using immunostaining. 
Both OFMSCs and ICMSCs were plated at a density of 8 X 103 cells/cm2 and 1.6 X 104 
cells/cm2 in an 8-well chamber slide. At 80% confluence, cells were treated with either 
0.1% or 21% O2 for 6 hours. Immediately after hypoxic treatment, hMSCs were rinsed in 
1x PBS and fixed in 4% paraformaldehyde for 10 minutes. Fixed cells were washed three 
times for 5 minutes each PBS, treated with 0.1% Triton X in PBS for five minutes at room 
temperature and then blocked with 3% normal goat serum prepared in 1% BSA and 
0.05% Triton X in PBS for 30 mins. Both groups of hMSCs treatment, were incubated in 
humidified tray with mouse monoclonal alpha smooth muscle actin (αSMA) (1:100 
dilution) and CD 146 (MUC18) (1:1000 dilution) (Abcam) at 40C overnight. A 1:500 dilution 
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of Alexa Fluor 488-labelled goat anti-mouse (Cell Signaling) was used as secondary 
antibody and counterstaining was done with 1 µg/mL Hoechst 33342. Both secondary 
incubation and counterstaining were carried out in the dark.  Fluorescence signals was 
analyzed using a Nikon epiflulorescence microscope. 
 
Post-hypoxic Cell survival 
Colony forming efficiency: 
To access post-hypoxia clonogenic properties of hMSCs were seeded at a density of 1.9 
X105 cells/cm2. At 80% confluence, hypoxic treatment with 0.1% oxygen was initiated for 
6 hours, with the control group treated at an oxygen tension of 21%. Cells were trypsinized 
and counted using a hemocytometer. hMSCs for colony forming efficiency were seeded 
in T-25 flasks at concentrations of 103, 102 and 101 and kept in culture for 14 days. Cells 
were fixed in absolute methanol and stained with methyl violet. Colonies containing 50 or 
more cell aggregates were counted and scored.  
 
Population doubling and lifespan of surviving OFMSCs: 
OFMSCs were plated with a cell density of 7.5 X 105 cells/flask. Expanded cells were re-
plated at a density of 1.9 X105 cells/cm2 and separated into normoxic and hypoxic 
treatment groups. At the end of the treatment cycle as previously described, hMSCs were 
trypsinized and counted. Population doubling capacity was determined based on 
repeated passaging at 1:10 split ratio until cells attained replicative senescence. 
 
Assessment of Apoptotic hypoxic-induced MSC death 
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Caspase 3/CPP32 Activity 
Cells were re-plated at a density of 1.7 x 105 cells/cm2. At 80% confluence, OFMSCs 
were exposed to either 0.1% or 21% O2 for 6 hours, trypsinized and counted to ensure 
approximately 5 x 106 cells were used for the cell activity assay. The counted cells were 
pelleted at 10,000g for 5 minutes at 40C. Pellets were re-suspended in lysis buffer 
(EnzoScientific NY, USA), incubated on ice and re-centrifuged at 10,000g for 1 minute to 
extract the cytosolic contents. After protein assay to determine protein amount, 50 µg/µl, 
was added to reaction buffer containing DTT and DEVD-pNA substrate. The mixture was 
incubated at 370C for 2 hours and absorbance read at 405nm in a spectrophotometer. All 
samples were tested in triplicates.  
 
Western blotting  
Using the protein lysates prepared above, immunoblotting was also carried out using 
equal protein amounts. The blots were probed with rabbit polyclonal caspase 3 antibody 
(Abcam) at 1:1000. This was followed by incubation in secondary antibody with Anti 
Rabbit, IgG HRP-linked antibody (Cell Signaling), using a 1:3000 dilution in 5% milk 
buffer.  β-actin (1:1000) served as loading control. Immunoreactive bands exposed with 
Konica Minolta developer (China) and analyzed using Image J. 
 
Assessment of hypoxia-induced autophagic responsiveness of hMSCs 
Autophagic response of undifferentiated hMSCs were determined following exposure of 
OFMSCs and ICMSCs to severe hypoxia. Following similar platting parameters described 
above cell lysate was collected and protein assay was performed so equal protein 
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amounts can be immunoblotted. LC3B a marker of autophagy was assessed by 
immunoblotting using rabbit polyclonal AntiLC3B (Abcam) and real time PCR was 
performed using custom made LC3b primer sequences: 5’ATT CGA GAG CAG CAT CCA 
AC-3’ (Forward) and 5’-CTG CCG TTC ACC AAC AG-3’ (Reverse). TATA binding protein 
served as internal control. Primer sequences were 5’-GGA GCT GTG ATG TGA AGT 
TTC CTA-3’ (Forward) and 5’-CCA GGA AAT AAC TCT GGC TCA TAA C -3’ (Reverse). 
Additionally, autophagic activity was further assessed by immunofluorescence. Both 
groups of hMSCs were re-plated at a density of 8 X 103 cells/cm2 and 1.6 X 104 cells/cm2 
in an 8-well chamber slide. At 80% confluence, cells were treated with either 0.1% or 21% 
O2 for 6 hours as previously described. Immediately after hypoxic treatment, hMSCs were 
fixed in 4% paraformaldehyde, rinsed in PBS-Tween 20 and then blocked with 5% normal 
goat serum in PBS-Tween 20 for 30 mins. hMSCs were incubated in humidified tray with 
3µg/mL and 4 µg/mL of rabbit polyclonal anti- LC3B antibody (Abcam) at 40C overnight. 
5 µg/mL of Alexafluor 488-labelled goat anti-rabbit (Cell Signaling) was used as 
secondary antibody followed by counterstaining with 1 µg/mL Hoechst 33342. 
Fluorescence signals was analyzed using a Nikon epiflulorescence microscope. 
 
Hypoxia-induced reactive oxygen species and oxidative stress 
Level of reactive oxygen species (ROS) induced by severe hypoxia was assessed using 
the dichlorofluorescein diacetate (DCFDA) cellular ROS Detection Assay kit (Abcam). 
OFMSCs were seeded on duplicate 96-well plates, at a density of 2.5 x 104 cells/ cm2 per 
well. At confluence, one plate was kept under normoxia, while the other was treated with 
0.1% O2. Cells were then washed and stained with 25μM of DCFDA for 45 minutes at 
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370C. Fluorescence signal was then read at 480nm.  Control hMSCs were not treated 
with DCFDA.  
 
In vitro osteogenic differentiation 
Osteogenic differentiation assay was  performed as  previously described (Akintoye et al 
2006; Damek-Poprawa et al 2010) using hMSCs plated at 1 x 104 cells/cm2.  OFMSCs 
from same individuals were each divided into 4 groups: 1). treated with either 21% O2 
(normoxia), 2). 6 hours of 0.1% O2 (severe hypoxia), 3). 7 days of sustained severe 
hypoxia (0.1% O2) followed by 7 days of normoxia, or 4). 14 days of 0.1% O2 sustained 
severe hypoxia. Each group of 4 treatment types were osteogenically stimulated for 14 
days and all the hypoxic groups were initially treated with unstimulated hypoxic medium 
for six hours before osteogenic induction. The osteogenic medium consisted of normal 
growth medium supplemented with 100µM L-ascorbic acid 2-phosphate (10-4M), 2mM 
dexamethasone sodium phosphate (American Regent Laboratories, Shirley, NY, USA). 
To assess in vitro mineralization (calcium deposition), similar experimental plates as 
above were set up but the osteogenic medium was fortified with 50mM β-
glycerophosphate. After 14 days, hMSCs in all the treatment groups were fixed in 10% 
formalin for one minute and rinsed with deionized water. Calcium accumulation based on 
mineralization assay was determined by staining with1% alizarin red dissolved in 2% 
ethanol. Unattached stain was rinsed copiously with deionized water. After air-drying the 
plates, attached alizarin red was quenched with 0.5N HCL and 5% sodium dodecyl 
sulphate (SDS) at room temperature for quantitative analysis. Absorbance was read in 
96-well plates at 405nm, using a microplate reader (Molecular Devices, USA). 
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Immunoblotting and real time PCR were also used to assess protein and RNA levels of 
the following osteogenic markers: Alkaline phosphatase, osteopontin osteocalcin and 
bone sialoprotein.  Rabbit polyclonal alkaline phosphatase placental (ALPP) (Novus 
Biologicals) and anti Osteopontin (Rockland Inc., USA) were used as primary antibodies 
while real time PCR was performed with these primers:  Osteopontin (OPN) (forward 5’-
TGGAAAGCGAGGAGTTGAATG-3’ and reverse CATCCAGCTGACTCGTTTCATAA-3’) 
Alkaline phosphatase (ALP): 5’-CCGTGGCAACTCTATCTTTGG-3’ (Forward) and 5’-
GATGGCAGTGAAGGGCTTCTT-3’ (Reverse)  
Bone Sialoprotein (BSP): 5’-AAC GAA GAA AGC GAA GCA GAA-3’ (Forward) and 5’- 
TCT GCC TCT GTG CTG TTG GT-3’ (Reverse) 
Osteocalcin (OCN): 5’- AAG AGA CCC AGG GCG GCT ACC T-3’ (Forward) and 5’- AAC 
TCG TCA CAAG TCC GGA TTG-3’ (Reverse). 
 
In vivo osteogenic differentiation 
Bone regenerative capacity of hypoxia-treated ICMSCs and OFMSCs was assessed by 
transplantation of 2 x 106 cells attached to 40mg spheroidal hydroxyapatite-tricalcium 
phosphate (particle size 0.5-1.0 mm, Zimmer, Warsaw, IN) into the subcutis of 8-week 
old immunocompromised female nude mice (NIH-III NU/NU, Charles Rivers Laboratories, 
Wilmington, MA) as previously established in Dr. Akintoye’s lab (The IACUC protocol was 
approved by the University of Pennsylvania office of Regulatory Affairs).  The hMSCs 
were divided into the treatment types described above under in vitro differentiation. Non-
induced and osteogenically induced OFMSCs and ICMSCs were transplanted into 4 
separate subcutis pocket of 5 different animals. At 6, 8 and 12 weeks, transplants were 
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harvested, fixed in 4% paraformaldehyde for 48 hours, decalcified in 10% EDTA (pH 8.0) 
and paraffin-embedded. Five micrometer sections were stained with hematoxylin/eosin 
for histological analysis. Digital images were captured with Nikon Eclipse80i fluorescent 
microscope (Nikon Instruments, Melville, NJ). Bone regeneration within the transplants 
was assessed using an established semi-quantitative bone scoring system 
(Akintoye,S.O. 2006):  Bone scores ranged from 0 (no bone formation observed in 
transplant); 1(minimal bone formed in transplant); 2 (weak bone formation in transplant, 
occupying a significant portion, but less than 50%);3 (moderate bone formation occupying 
a significant portion but less than 50% of the transplant) and 4 (abundant bone formation, 
occupying more than 50% of transplant).  
 
Adipogenic differentiation 
ICMSCs and OFMSCs were cultured at 1.8 x 10³ cells/cm2. At 90% sub confluence, 
adipogenic differentiation was induced using established adipogenic parameters for 21 
days (Akintoye et al 2006; Osyczka et al 2002). Adipogenic medium contained 10-8M 
dexamethasone, insulin (1µg/ml), 5 X 10-8 M 1-methyl-3-isobutylxanthine (IBMX) ,10-4 M 
indomethacin and ten percent (10%) fetal bovine serum (FBS), penicillin, streptomycin, 
glutamate and alpha MEM. Adipogenically induced ICMSCs and OFMSCs were 
subjected to the following treatments: normoxia treated for 21 days, 7 days of sustained 
hypoxia followed by 14 days of normoxia, 14 days of sustained hypoxia followed by 7 
days of normoxia and 21 days of sustained hypoxia. The control group hMSCs were not 
induced adipogenically but retained in normal growth medium. At 21days, hMSCs were 
washed in phosphate buffered saline, fixed in 4% paraformaldehyde for 10 mins at room 
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temperature, stained with Oil Red O for 1 hour and counterstained with 1% fast green dye 
for another 10 minutes. Lipid laden cells were evaluated and quantified microscopically 
to determine the number of adipocytes. In parallel experiments, protein and RNA were 
collected to quantify markers of by western blotting and real time PCR respectively. 
Primary antibodies to peroxisome- proliferator-activated receptor gamma (PPAR 
gamma), an early marker of adipogenesis and cytoplasmic phospholipase A2 (PLA2) (late 
marker of adipogenesis) were used for immunoblotting. The following primers were used 
for real time PCR: peroxisome- proliferator-activated receptor gamma (PPAR gamma) 
(primers: forward 5’TGAATGTGAAGCCCATTGAA-3’ and reverse 5’-
AGCGGGTGAAGACTCATGTC-3’); phospholipase A (cPLA2) (primers: forward 5’-
GGGGGCCTTTGGTGACATGCT-3’ and reverse 5’-ACCACAGGCACATCACGTGCA-3’) 
and LPL (primers:5’- ACG GCA TGT GAA TTC TGT GA -3’(forward) and 5’- GGA TGT 
GCT ATT TGG CCA CT -3’ (reverse), which are early and late markers of adipogenesis.  
 
Assessment of HIF-dependent response of OFMSC to severe hypoxia 
HIF-1 alpha expression of OFMSCs under normoxia and severe hypoxia were assessed 
by immunofluorescence, immunoblotting and real time PCR. Primary antibody of mouse 
anti-HIF-1α (Abcam) at 1: 1000 dilution was used for both immunoblotting and 
immunofluorescence. Secondary antibodies were Alexafluor 488 (1:500 dilution) and 
Alexaflour 555 (1:500 dilution) for immunofluorescence and anti-mouse (1:3000) for 
immunoblotting. Counterstaining was carried out with 1μg/ml of Hoechst 33342. HIF-1α 
primer sequences for real time PCR were: 5’-ACG TTC CTT CGA TCA GTT GTC A-3’ 
(forward) and 5’-TTT GAG GAC TTG CGC TTT CA-3’ (reverse). 
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Assessment of OFMSCs endoplasmic reticulum stress response post severe 
hypoxia 
OFMSCs protein lysate and RNA samples were collected post severe hypoxia. 
Immunoblotting and real time PCR were used to assess the activation of endoplasmic 
reticulum stress response (ERSR) in OFMSCs following treatment with 21% and 0.1% 
oxygen tensions as described above. The following ERSR markers were assessed: 
eukaryotic initiation factor 2α (eIF2α), phosphorylated eukaryotic initiation factor 2α 
(peIF2α), activating transcription factor 4 (ATF4), and binding protein (Bip).  
 
For immunoblotting, equal protein amounts were used to determine the expression levels 
of Bip and eIF2α. The blots were probed with rabbit polyclonal anti-Bip (1:1000) (BD 
Biosciences) mouse anti-eIF2α (1:1000) (Cell signaling Technology); rabbit anti-peIF2α 
(1:500) (Cell signaling Technology); and rabbit anti-ATF4 (1:500). Secondary antibodies 
were anti Rabbit and anti-mouse, IgG HRP-linked antibodies (Cell Signaling) respectively 
at 1:3000 dilution in 5% milk buffer.  Anti-β-actin (1:1000) served as loading control. 
Immunoreactive bands were developed with a Konica Minolta developer (China) and 
analyzed using Image J software. 
Real time PCR was carried out with 7300 Fast Real Time PCR system (Applied 
Biosystems, Foster city, CA) as previously described above. The following custom 
designed primers were used: Bip: 5’- GGA GGT GTC ATG ACC AAA CTG A -3’ (forward) 
5’TCT TTC ACC TTC ATA GAC CTT GAT TG-3’ (reverse); ATF4: 5’-CAG ACC GTG 
AAC CCA ATT GG -3' (forward) and 5’- CAA CCT GGT CGG GTT TTG TT-3' (Reverse). 
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Assessment of activation of vascular endothelial growth factor (VEGF) 
VEGF expression was also assessed by western blotting, real-time PCR and 
immunofluorescence to evaluate the role of the two independent pathways in the recovery 
of OFMSCS after severe hypoxia. Mouse anti-human VEGF antibody (Abcam) was used 
for both immunoblotting (6μg/ml) and immunofluorescence (1:2000 dilution).  
VEGF primer used for real time PCR were:  5' GCA CCC ATG GCA GAA GGA GG-3' 
(forward) and 5'CCT TGG TGA GGT TTG ATC CGC ATA -3' (Reverse) 
The physiologic effect on blood vessels in vivo was also assessed by 
immunohistochemistry.  
 
Pharmacologic perturbation of HIF-1α and ERSR and effects on VEGF activation 
OFMSCs were divided into the two treatment groups as previously described above. Cells 
were treated for 18 hours with Thapsigargin (1μM), Integrated stress response inhibitor 
(ISRIB) 0.2mM (ER stress response upregulator and downregulator respectively) as well 
as quinomycin (80nM) and 2,4 diethylpyridine dicarboxylate (50	 μM) (HIF-1α 
downregulator and upregulator respectively).  While a set of cells were kept under 
normoxic conditions, another set was switched after 12 hours and exposed to 0.1% 
oxygen for an additional 6 hours. Effect of upregulation and downregulation of HIF-1 alpha 
and ERSR on VEGF levels were assessed by real time PCR.  
 
Statistical analysis 
	 42	
Experiments were analyzed using Prism 6 (GraphPad Software Inc. La Jolla CA).  Each 
set of experiments was performed at least three times and cells were set up in triplicates 
plates. All data were subjected to descriptive analysis and expressed as mean ± standard 
deviation. Relationship between cells treated at 21% and 0.1% oxygen was assessed by 
paired t-test and differences among subjects were assessed by one-way analysis of 
variance (ANOVA) followed by post-hoc analysis with Bonferroni correction. Statistical 
significance was set at p<0.05. 
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CHAPTER FOUR 
4.0 RESULTS 
hMSCs succumb to severe hypoxia 
Following exposure of hMSCs from 3 different healthy patients to varying oxygen 
concentrations of 21% (normoxia), 2% and 0.1%, both ICMSCs and OFMSCs were noted 
to succumb to severe hypoxia of 0.1% O2 (Figure 8).  
 
 
Figure 8. Response of hMSCs (both ICMSCs and OFMSCs) to different oxygen 
concentrations 
MSCs were treated in 21%, 2% and 0.1% oxygen tensions. OFMSCs at 0.1% O2 was 
noted to succumb more to severe hypoxic insult, with a 0.5-fold decrease (p < 0.01) 
when compared to ICMSCs treated under the same conditions. ICMSCs in the hypoxic 
group showed a 0.1-fold decrease compared with normoxia. Fold change in cell number 
was relative to MSCs treated under 21% O2 tension 
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However, over 50% of OFMSCs were noted to succumb to severe hypoxia, compared to 
10% of ICMSCs (p < 0.01). To recapitulate severe hypoxia in subsequent experiments, 
an oxygen concentration of 0.1% was selected. Most of the subsequent experiments 
focused on OFMSCs while ICMSCs were used as non-orofacial controls. 
 
Selection of optimal time point for hypoxic treatment  
OFMSCs were further exposed to 0.1% oxygen for 1, 3 and 6 hours to assess time-
dependent effect of severe hypoxia on hMSCs. Comparison of percentage of surviving 
and dead cells demonstrated that 6 hours was an optimum time point of maximum cell 
survival (Figure 9). Six-hour time point was designated as t50, at which 50% of hMSCs 
were still viable. Exposure of hMSCs to severe hypoxia was conducted for 6 hours. Any 
exposure beyond 6 hours was regarded as sustained severe hypoxia   
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Severe hypoxia activated oxidative stress and release of reactive oxygen species 
by OFMSCs.  
In addition, post-hypoxic production of reactive oxygen species was assessed in the 
OFMSC treatment groups. Under severe hypoxia, there was a significant 8-fold increase 
in the detection of reactive oxygen species (ROS) activity by OFMSCs (p< 0.01) (Figure 
10).	 
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Figure 9. Post-hypoxic percentage of surviving cells relative to dead cells. 
Time-dependent changes in ratio of live to dead cells after exposure of OFMSCs to 
severe hypoxia	
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Effect of severe hypoxia on expression levels of OFMSC markers of ‘stemness’. 
After exposure of OFMSCs and ICMSCs to severe hypoxia, the expression levels of two 
major markers of MSC ‘stemness’, α-SMA and MUC18 (CD146) were assessed by 
immunofluorescent staining. Results showed that both α-SMA and MUC18 
immunofluorescence signal intensities were relatively reduced in OFMSCs compared to 
ICMSCs. Approximately 250-fold decrease in signal intensity of α-SMA was noted in 
OFMSCs (Figure 11) treated under severe hypoxia compared with ICMSCs (p < 0.001) 
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Figure 10. Post-hypoxic oxidative stress based on levels of reactive oxygen 
species. 
OFMSC oxidative stress based on ROS production was significantly higher under 
hypoxic stress relative to normoxia (n =3, p < 0.01).	
*** 
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and a 2-fold decrease was noted in fold intensity of MUC18 in the OFMSC severe hypoxia 
treatment group (p < 0.01) (Figure 12). 
 
 
	
	
	
	
A B 
***	
Figure 11. Comparative difference in OFMSC and ICMSC expression levels of 
αSMA.	
ICMSCs (upper panel) after exposure to 0.1% oxygen showed higher 
immunofluorescent signal intensity compared to OFMSCs treated under similar 
conditions (lower panel right- 11A). Normoxia (control) MSCs were exposed to 21% 
oxygen tension) (left upper and lower panel (11A). Quantitative analysis of signal 
intensities (11B) also demonstrated the significant differences in αSMA expressions 
between OFMSCs and ICMSCs (*** P < 0.0001).	
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Post-hypoxic OFMSC survival 
Cell proliferation/Population Doubling 
Furthermore, post-hypoxic recovery capacity of OFMSCs was assessed directly and 
indirectly following evident presence of fewer surviving OFMSCs after hypoxic treatment. 
Assessment of population doubling properties of the hMSCs demonstrated survival up to 
A B 
Figure 12. Comparative difference in OFMSC and ICMSC expression levels of 
MUC18.	
ICMSCs (upper panel) after exposure to 0.1% oxygen showed stronger 
immunofluorescence signal intensity compared to OFMSCs treated under the same 
conditions (lower panel right- 12A). Normoxia (control) MSCs were exposed to 21% 
oxygen tension) (left upper and lower panel- 12A). Quantitative analysis of signal 
intensities (12B) also demonstrate a difference in MUC18 expressions between 
OFMSCs and ICMSCs 
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50 population doublings in the hypoxia-treated OFMSCs. The normoxic-treated cells 
however, survived up to 60 population doublings (Figure 13).  
 
 
Indirect evaluation of OFMSC recovery capacity by assessing apoptosis showed a 0.2-
fold decrease (p= 0.076) (Figure 14A & 14B) in expression of Caspase 3 (apoptotic 
marker) in the hypoxic group (by immunoblotting). This was further confirmed by a 0.1-
fold decrease in Caspase 3/CPP activity in the hypoxic group (p = 0.49) (Figure 14C). 
Figure 13. Post hypoxic population doubling capacity of OFMSCs 
Similar proliferation patterns between the normoxic and hypoxic groups of 
OFMSCs. OFMSCs treated under hypoxic conditions were noted to survive up 
to 50 population doublings (PD), while the normoxic treatment group survived 
up to 60 PD. [Representative graph of one of the patient samples; n=3 samples. 
(p = 0.356).	
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The expression level of LC3, a marker of autophagic activity was further assessed by 
immunoblotting, real time PCR and immunofluorescence. Hypoxia-treated OFMSCs 
displayed a 0.3-fold decrease in protein expression of LC3 (p= 0.05) (Figure 15A & 
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Figure14. Apoptosis in hypoxic-treated OFMSCs. 
A 0.2-fold decrease in caspase-3 protein expression noted in the hypoxia-treated 
group (p = 0.076) (14A & 14B). Caspase 3/CPP activity by colorimetric assay further 
showed a 0.1-fold decrease in the hypoxic treatment group when compared to 
normoxia. (14c) (p = 0.49).	
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15B). A more significant difference was noted in LC3 gene expression, with a 0.7-fold 
decrease in the hypoxic group (p= 0.011) (Figures 15C). This was further supported by 
the fewer immunoreactive cells in the hypoxic group based on immunofluorescence 
staining (Figure 15D). 
 
 
 
 
Figure 15. Comparative differences in LC3 expression	
LC3 a marker of autophagic activity was assessed by immunoblotting (15A, 15B) and 
real time PCR (15C). A 0.2-fold and 0.6-fold decrease was noted in the hypoxic 
treatment group following immunoblotting and real-time PCR (p = 0.05) respectively. 
Additional immunofluorescent staining also confirmed decreased immunoreactive 
hypoxic treated OFMSCs (15D).	
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Finally, a comparable colony forming efficiency pattern was observed in both the 
normoxic and hypoxic treatment groups with an average of 5 x 105 colony forming units 
(CFUs) in each group (Figure 16). 
 
 
 
 
Post hypoxic OFMSC differentiation: 
Effect of severe hypoxia on in vitro osteogenic differentiation 
Normoxia 
OFMSCs Colony forming units 
Hypoxia 
Figure 16.  Colony forming efficiency in response to severe hypoxia.  
Both normoxic and hypoxic cells displayed similar clonogenic capacity [red star 
identifies some representative clones	
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Osteogenic differentiation capability of surviving OFMSCs post hypoxia was also 
assessed, with comparable osteogenic differentiation noted in both hypoxic-treated and 
normoxic-treated groups. This was noted with Alizarin red dye stain (Figure 17). 
Quantitative analysis however showed a 0.4-fold increase in mineralized OFMSCs in the 
severe hypoxia treatment group when compared with those treated with normoxia (p = 
0.51) (Figure 18).   
 
 
 
When gene expression of bone markers was evaluated by real time PCR, the hypoxic 
treatment group showed non-significant decreased ALP, OCN and BSP activity (Figures 
Figure 17. Post-hypoxic osteogenesis based on in vitro mineralization 
In vitro mineralization of OFMSCs based on alizarin red staining were not affected by 
hypoxia as both normoxic and hypoxic cells displayed similar staining patterns. The 
non-osteogenically stimulated cells served as control.	
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19, 20, 22). OPN however had a comparable expression between the normoxic and 
hypoxic treatment groups (Figure 21).  
	
	
 
 
 
 
Figure 18. Post-hypoxic osteogenic differentiation of OFMSCs based on in vitro 
mineralization 
Quantitative analysis of mineralization shows a non-significant increase in mineral 
deposition in the severe hypoxic treatment group. [n =3] [p = 0.51]. 
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Further assessment of osteogenic markers by real time PCR showed a non-significant 
decrease in gene expression of ALP, BSP and OCN (0.3-fold decrease) in the OFMSC 
hypoxic treatment group (Figure 19-22). OPN however showed similar expression 
between the two treatment groups (Figure 21). 
 
 	
	
Figure 19. Post-hypoxic osteogenic differentiation based on alkaline 
phosphatase (ALP) gene expression 
Gene expression of ALP in OFMSCs treated under normoxic and hypoxic treatment 
conditions. The reduced level of ALP in hypoxic treated OFMSCs was minimal and 
non-significant.	
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Figure 20. Post-hypoxic osteogenic differentiation based on bonesialoprotein 
(BSP) gene expression 
Gene expression of BSP in OFMSCs treated under normoxic and hypoxic treatment 
conditions was assessed by real time-PCR. BSP showed decreased expression in the 
hypoxic treatment group but was not significant. 	
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. 	
	
Figure 21. Post-hypoxic osteogenic differentiation based on osteopontin (OPN) 
gene expression. 
Gene expression of OPN in OFMSCs treated under normoxic and hypoxic treatment 
conditions assessed by real time-PCR showed comparable expression levels in both 
treatment groups. 	
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Figure 22. Post-hypoxic osteogenic differentiation based on osteocalcin (OCN) 
gene expression 
OFMSCs treated under normoxic and hypoxic treatment conditions assessed by real 
time PCR showed a 0.2-fold decreased expression level in the hypoxic treatment 
group.  
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Effect of severe hypoxia on in vivo osteogenic differentiation  
 
In addition to in vitro osteogenesis, the ability of OFMSCs to recover from hypoxic insult 
and form bone was also assessed in vivo.  H&E staining of normoxic and hypoxic treated 
OFMSCs harvested from the subcutis of immunocompromised mice after 8 weeks of 
transplant (Figure 23 & 24), showed similar bone formation pattern within the 
hydroxyapatite in both groups.  An average bone score of 4 was assessed in each group. 
 
 
 
 
Figure 23. Transplantation of OFMSCs post-hypoxia.  
A representative immunocompromised nude mouse showing transplanted OFMSCs 
with carrier before and after surgical exposure and harvesting.	
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Figure 24. Photomicrograph of H& E stained sections of tissue formed 
from transplanted OFMSCs 
Harvested transplants of OFMSC treated under normoxic conditions (24A 
above) showing bone formation (black arrow) within the hydroxyapatite after 8 
weeks of transplant.Similar bone formation pattern noted in OFMSCs treated 
under hypoxic conditions (24B below). [Magnification 20x] 
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Adipogenesis 
In further assessing the effect of severe hypoxia on differentiation, OFMSCS were 
induced adipogenically for 21 days post hypoxia. Oil red-O staining following fixation with 
4% formaldehyde showed the presence of adipocytes in both treatment groups. This was 
evidenced by bead-like red stains in the perinuclear area of the cells as shown in Figure 
25.  
Additionally, assessment of adipogenic markers post-hypoxia showed a 0-2-fold (p= 0.4) 
and 0.5-fold (p =0.01) in PPAR gamma and LPL levels respectively (Figure 26, 27), when 
assessed relative to hypoxia by real time real time PCR. Protein expression of 
cytoplasmic phospholipase A2, showed a 0.1-fold decrease (p =0.8) in the hypoxic 
treatment group (Figure 28).  
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Figure 25.	Post-hypoxic	adipogenic differentiation based on Oil Red O staining. 
The red staining sections show adipocytes surrounding nuclei in normoxic treated 
OFMSCs (25A, above) and severe hypoxic treated OFMSCs (25B, below). 
Counterstaining carried out with fast green dye. 
	
A	
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Figure 26. Post hypoxic adipogenic differentiation in OFMSCs based on PPAR 
gamma expression. 
PPARgamma, a marker of adipogenesis was expressed similarly by both normoxic and 
hypoxic treated OFMSCs (p = 0.4). 
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Figure 27. Post hypoxic adipogenic differentiation in OFMSCs (Lipoprotein 
lipase)  
Lipoprotein lipase, a marker of adipogenesis showed a 0.5-fold increase in gene 
expression in the hypoxic group (p = 0.01). 
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Figure 28. Post hypoxic adipogenic differentiation in OFMSCs based on 
expression levels of cytoplasmic phospholipase A2. 
There was minimal difference in expression levels of cytoplsmic phospholipase 
A2 between the normoxic and hypoxic groups (p = 0.8). 
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Role of HIF1 in responsiveness of OFMSCs to hypoxia 
Mechanistically, HIF-1α signaling pathway, a pathway that regulates cellular response to 
hypoxic stress when assessed by immunofluorescence, immunoblotting real time PCR in 
OFMSCs showed the presence of more positive cells (Figure 29) and increased 
expression levels in the hypoxic treatment group. While protein expression showed a 0.4-
fold increase (p =0.015) (Figure 30B & 30B), gene expression demonstrated a 0.1-fold 
increase (p=0.77) (Figure 30C). 
 
 
 
	
 
 
Figure 29. HIF-1α activation in hypoxic OFMSCs 
There was a higher number of HIF-1α positive OFMSCs activated by severe hypoxia 
based immunofluorescent staining with anti-HIF-1α	
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Figure 30. Post-hypoxic assessment of HIF-1α levels  
Activation of HIF-1α is demonstrated by 0.4-fold increase by immunoblotting (p 
=0.015) (30A & 30B) and minimal 0.1-fold increase based on real time PCR (p=0.77) 
(30C)	
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Post-hypoxic assessment of ER stress response pathway: 
In addition to the mechanistic assessment of HIF-1α, markers of ER stress response 
signaling pathway, a pathway that responds to cellular stress was evaluated. A 0.5-fold 
(p =0.28) (Figure 31A & 31B) and 5-fold (p =0.036) (Figure 32) increase in BiP and 
phosphorylated eIF2α protein expression levels respectively was noted in the hypoxic 
treatment group. 
Furthermore, gene expression of ATF6, which is upstream of phosphorylated eIF2α in 
ER stress response pathway showed a 0.5-fold (p = 0.28) increase in the hypoxic 
treatment group (Figure 33).  
 
 
 
 
 
0
0.5
1
1.5
2
Normoxia Severe
Hypoxia
fo
ld
	c
ha
ng
e	
re
la
ti
ve
	to
	
no
rm
ox
ia
BiP
Actin 
BiP 
Normoxia S. Hypoxia 
A B 
Figure 31. Assessment of post-hypoxic ER stress responsiveness of 
OFMSCs based on Bip level 
Activation of  Bip a responsive element in the ERSR pathway is minimally higher 
based on immunoblotting. 	
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Figure 32. Assessment of post-hypoxic ER stress responsiveness of 
OFMSCs based on activation of the PERK arm of ERSR  
The level of  phosphorylated eIF2α based on immunoblotting shows a significant 
5-fold (p =0.036) increased in the hypoxic treatment group of OFMSCs.	
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Figure 33: Post hypoxic ER stress response pathway assessment (PERK signals) 
The level of ATF4 downstream of phosphorylated eIF2α based on immunoblotting 
shows a minimal 0.5-fold  (p =0.036) increased in the hypoxic treatment group of 
OFMSCs.	
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Interplay between HIF-1α and ERSR pathways 
We further assessed the interplay between the two mechanistic pathways (HIF-1α and 
ERSR) with and without chemical upregulation and downregulation of both pathways. 
Gene expression of HIF-1α showed a 3.5- fold increase (p= 0.015) in the hypoxic 
treatment OFMSC group, after 18 hours of chemical upregulation of the ERS response 
pathway by thapsigargin (Figure 34). 
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Figure	34.  Combined effects of severe hypoxia and ERSR on OFMSCs. 
HIF-1α expression in OFMSCs was significantly upregulated by the combined effects of 
severe hypoxia and ERSR relative to hypoxia only. Fold change is relative to OFMSCs treated 
with normoxia only. (p = 0.015) 
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The HIF-1α pathway inducer and downregulator evaluated were 2,4-DPD and 
Quinomycin respectively.  
 
 
 
 
Protein expression of Quinomycin when assessed relative to OFMSCS not chemically 
stimulate, showed an approximately 2-fold increase in the normoxia treatment group and 
no changes in the hypoxic treatment group. On the other hand, OFMSCs treated with 2,4-
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Figure 35: Effects of blockage and upregulation of HIF-1α under severe hypoxia. 
While the combination of quionomycin with severe hypoxia showed no effects 
compared to normoxia, the upregulation of HIF-1α .by 2,4-DPD was attenuated under 
severe hypoxia (** p < 0.05)	
**	
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DPD produced a 10-fold  and 6-fold increase in HIF-1 α expression under normoxia and 
severe hypoxic conditions respectively (Figure 35). 
 
 
	
 
  
 
 
Figure 36: Effects of blockage and upregulation of HIF-1α under severe hypoxia. 
While the combination of quionomycin with severe hypoxia showed no effects compared 
to normoxia, the upregulation of HIF-1α .by 2,4-DPD was attenuated under severe 
hypoxia (** p < 0.05)	
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Further interactions between both pathways was assessed by evaluating expression level 
of ATF4 after upregulation and downregulation of HIF-1α in both treatment groups. A 26-
fold increase was noted in the expression level of ATF4 following normoxic treatment of 
OFMSCs with 2, 4-DPD, while an approximate 8-fold increase was noted under severe  
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Figure 37: Combination of severe hypoxia and ERSRS activates HIF-1α  
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hypoxia. On the other hand, expression of ATF4 in quinomycin treated OFMSCs under 
normoxic and hypoxic conditions, showed similar patterns with the group treated without 
any inducers or downregulators. (Figure 36). 
Finally, gene expression of HIF-1α was also assessed following induction and 
downregulation of ERS response, using Thapsigargin and ISRIB respectively. A 2.5-fold 
increase was noted in HIF-1α response of OFMSCs treated under both severe hypoxia 
and ER stress induction (thapsigargin) (Figure 37).  
 
Post hypoxic assessment of VEGF expression 
Since VEGF is downstream of both HIF and ERSR signaling pathways, we assessed the 
effect of severe hypoxia on both pathways. A 1-fold increase (p = 0.017) in gene 
expression was noted in the severe hypoxic treated group when compared with normoxia 
(Figure 38A). This was further confirmed by immunohistochemistry (Figure 39), which 
showed more reactive VEGF on tissue sections from the harvested transplants in the 
hypoxic treatment group. Protein expression however showed no significant differences 
between the two treatment groups (Figure 38B). 
The effect of HIF-1α and ERS response pathways on VEGF expression was also 
assessed by chemical inhibition and enhancement of both pathways. VEGF gene 
expression was noted to be 16-fold and 8-fold higher in the normoxic and severe hypoxic 
treatment group pretreated with 2,4 DPD (Figure 40) respectively. Finally, when OFMSCs 
were induced by thapsigargin, the hypoxic treatment group showed approximately 5-fold 
increase compared to the normoxic group (Figure 41) (p=0.00085). 
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Figure 38: Post hypoxic recovery of OFMSCs (VEGF expression- in vitro) 
Gene expression of VEGF shows significant upregulation in severe hypoxic 
treatment group when compared with normoxia, with a 0.8-fold increase in the 
hypoxic treatment group (p= 0.017). Protein expression however show no difference 
between the two groups. 
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Figure 39: Post hypoxic recovery of OFMSCs based on in vivo bone 
regeneration and VEGF expression 
H&E staining of the transplant tissue. Shows bone formation within the 
hydroxyappatite. More bone formation noted in the severe hypoxia treatment group. 
Image below shows VEGF expression within the hard and soft tissues, with more 
VEGF expresson noted in the transplant pretreated with hypoxia. 
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Figure 40: Post hypoxic recovery of OFMSCs based on VEGF expression 
Gene expression of VEGF shows significant upregulation in severe hypoxic 
treatment group when compared with normoxia, with a 0.8-fold increase in the 
hypoxic treatment group (p= 0.017). Protein expression however show no difference 
between the two groups (data not shown). 
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Figure 41: Interplay of ERSR pathway induction and hypoxia on OFMSCs VEGF 
expression.  
Gene expression of VEGF in the two treatment groups pretreated with 1mM of 
thapsigargin. VEGF expression noted to be higher in the severe hypoxic treatment 
group. (p=0.00085) 
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CHAPTER FIVE 
 
5.0 DISCUSSION 
 
Bone MSCs within the bone marrow depend on a physiologic hypoxic niche to effectively 
maintain their ‘stemness, renewal, survival and differentiation properties (Hu X. et al 
2014). A combination of stem cell resistance and adaptation to this hypoxic milieu is likely 
responsible for preserving the phenotypic and functional MSC properties of MSCs 
(Buravkova, 2014).  
There is meager information on responsiveness of orofacial MSCs to non-physiological 
hypoxia. Most of the previous studies on effects of severe hypoxia on MSCs tested 
physiological hypoxia rather than severe hypoxia. This is because the oxygen tension 
used for the studies was compared to atmospheric oxygen in vitro rather than the 
physiologic oxygen conditions that MSCs are familiar with (Hu, X. 2014, Xu 2014, 
Holzwarth 2010, Ito 2015, Grayson 2007). Furthermore, orofacial MSCs were not 
included despite the fact that MSCs from many other body sites were tested (Hu, X. 2014; 
Ito, A. 2015;  Holzwarth,C. 2010; Xu,L. 2014; Grayson,W.L. 2006) 
Orofacial MSCs were the focus of this project because of its clinical relevance to 
pathophysiology and management outcomes of jaw osteoradionecrosis, a major cancer 
complication of head and neck radiation therapy. Hypoxia plays a central role in the 
hypoxic-hypovascular-hypocellular mechanistic theory of ORN pathogenesis. 
Additionally, MSCs are phenotypically and functionally unique based on their 
embryological site of origin.  
	 81	
To simulate radiation-induced hypoxia, we used a hypoxic chamber to induce severe 
hypoxia at 0.1% oxygen tension. In assessing the effect of severe hypoxia on human 
OFMSC plasticity, we utilized 0.1% O2 tension in a hypoxic chamber. Severe hypoxia was 
tested in this project because stem cells in general are resistant to low oxygen tensions 
that exist at physiologic levels (around 2% O2) (Buravkova,L.B. 2014), while extremely 
low oxygen tension induces pathologic effects (Martin-Rendon,Enca 2007). Our study 
noted that when compared to OFMSCS treated under normoxic (21% O2) and physiologic 
hypoxic (2% O2) conditions, OFMSCs treated with severe hypoxia (0.1% oxygen) 
succumbed to the hypoxic insult. A similar finding was reported by Hutton et al in 2016. 
The authors noted that adipose-derived MSCs from female patients succumbed to 
hypoxic treatment with oxygen tension of 0.2% (Hutton 2016). Our data also suggest that 
severe hypoxia can change the MSC population because undifferentiated pool of 
osteoprogenitors were severely depleted based on decrease in STRO1+, CD146 and α-
SMA positive cells. The implication of this effect is that when severe hypoxia depletes 
OFMSCs osteoprogenitors, there are fewer osteogenically active cells that can 
differentiate to pre-osteoblast. Hence, recovery and bone regeneration post-hypoxia is 
severely suppressed. This undoubtedly underscore the role of hypoxia in the 
pathogenesis of jaw ORN.  
To further compound the suppression of osteoprogenitors, the increase production of 
ROS and oxidative stress under severe hypoxia will further reduce the number of 
surviving OFMSCs(Cicione C. 2013). The interplay of depleted osteoprogenitors, ROS, 
oxidative stress and decreased OFMSCs survival further enhance jaw susceptibility to 
ORN. 
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Since the population of MSCs changed after severe hypoxia, it is imperative to access 
the recovery capacity of residual MSCs that overcome severe hypoxia. The premise is 
that if a some MSC populations survive radiotherapy-induced hypoxia, it may be possible 
to reactivate these cells, promote post-hypoxic healing and reduce susceptibility to ORN. 
Interestingly, surviving OFMSCs displayed appreciable population doubling capacity and 
colony forming efficiency and decreased autophagic and apoptotic activities in spite of 
exposure to severe hypoxia. These outcomes are in line with a previous report that 
showed increased MSC proliferation at physiologic hypoxic conditions (Pal Singh,R. 
2012). A similar pattern was also reported by Buravkova in 2004, where MSCs exposed 
to short-term hypoxia (up to 72 hours) displayed decreased viability but equivocal 
response to proliferation and increased reactive oxygen species production (Buravkova 
2014).  Another study showed increased colony forming efficiency in cord blood MSCs 
treated exposed to hypoxia (1.5%) (Martin-Rendon,Enca 2007) These reports are 
consistent with the premise that MSCS and in this case OFMSCs can adapt to 
environmental stress following severe hypoxia (Greijer, A. E. 2004). Greijer also stated 
that the severity and length of time of exposure to hypoxia determines if cells undergo 
apoptosis or environmental adaptation. Our study observed that exposure to acute severe 
hypoxia resulted in OFMSC adaptation rather than apoptosis. It will be interesting to 
further evaluate the effect of severe and prolonged hypoxia on OFMSCs as these will 
further simulated the repeated cycles of radiotherapy associated with management of 
head and neck cancers. 
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In addition to maintaining proliferative ability under severe hypoxic conditions, OFMSCs 
were also noted to maintain osteogenic and adipogenic differentiation capability. This is 
an interesting finding, considering that hypoxia-induced depletion of osteoprogenitors 
should negatively affect osteo-differentiation ability. In essence, OFMSCs did not only 
recover from severe hypoxic insult but were able to retain some degree of differentiation 
ability. Other studies have also suggested that severe hypoxia alters multilineage 
differentiation pattern of MSCs from non-oral skeletal sites (Cicione C, et al 2013; 
Holzwarth,C. 2010). Holzwarth et al in 2010, showed comparable adipogenic and 
osteogenic differentiation between human MSCs cultured at 21% and those cultured at 
3%. Most of these studies however, are not comparable to our study as physiologic 
oxygen tensions were assessed and none of the MSCs studied were from the orofacial 
region.      
Furthermore, HIF-1α was noted to be activated after severe hypoxic treatment, assessed 
by immunofluorescence, immunoblotting and real time PCR. A similar observation 
reported by Lynam et al in 2015, showed increased in HIF-1α level following severe 
hypoxic treatment (0.5% O2). (Lynam,E.C. 2015). Similar studies that assessed HIF-1α 
expression in mice bone marrow MSCs (Ren,Hongying 2006) and human MSCs  (Xu. H. 
2014) have also reported increased HIF-1 activation under severe hypoxia.  Our findings 
combined with these previous studies underscore the modulatory roles of HIF-1α 
signaling in MSCs survival post severe hypoxia.  
An important downstream effector of HIF-1α signaling is VEGF. HIF-1α has been noted 
to increase VEGF production under hypoxic conditions (Razban, V. 2012).  It was 
significant to note that VEGF expression was activated in OFMSCs in response to severe 
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hypoxic treatment. Umbilical cord MSCs have also been shown to expressed increased 
VEGF levels in response to severe hypoxia (Martin-Rendon,Enca 2007). The protective 
effect of bone marrow MSCs on cardiomyocytes has been previously demonstrated . 
Bone marrow MSCs transplanted into an ischemic cardiac environment were able to 
survive and activated increased HIF-1α-medicated VEGF levels in the hypoxic 
environment ( Razban V. 2012). Based on our data, the ability of hypoxic treated OFMSCs 
to activate both HIF-1α and VEGF suggest that residual MSCs post-radiotherapy can be 
activated to improve recovery from jaw ORN. This can be induced by grafting autologous 
OFMSCs into an osteoradionecrotic area in the jaw. The activity of the donor MSCs have 
the potential to reactivate residual cells to promote HIF-1α-VEGF associated survival and 
recovery.  
 
In addition to HIF-1α signaling pathway, the PERK- eIF2α arm of the endoplasmic 
reticulum stress response pathway was also activated in OFMSCs in response to severe 
hypoxia. The significant increase in eIF2α indicates that ERSR pathway will slow down 
protein translation to reduce accumulation of unfolded proteins in the endoplasmic 
reticulum in response to hypoxic stress (Simon, M.C. 2008). It is interesting to note that 
both HIF-1α  and PERK-eIF2α arm of the ERSR are upstream effectors of VEGF (Figure 
??). (Simon, M.C. 2008), (Tamama, K. 2011). Since VEGF level was significantly 
upregulated in hypoxia-treated OFMSCs, the recovery of OFMSCs and ability of residual 
cells to retain osteogenesis can be attributed to cooperation of angiogenesis and 
osteogenesis signaling pathways. Hence angiogenesis-osteogenesis cooperation is 
major factor essential for post-hypoxia recovery of OFMSCs.  
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Conclusion  
Severe hypoxia possibly plays a huge role in the pathogenesis of jaw osteoradionecrosis. 
Even though OFMSCs succumb to severe hypoxia, they are able to recover and retain 
their stem cell properties. This shows a potential usefulness of autologous MSCs as 
transplants in the management of patients with jaw osteoradionecrosis.  
However, before drawing any definite conclusions from this study, it will be advantageous 
to consider the effects of long-term sustained hypoxia on OFMSCs. An essential future 
direction is the need for both pharmacologic and genetic disruption of HIF-1α and PERK-
eIF2α signaling pathways to further confirm their roles in OFMSC responsiveness to 
severe hypoxia.   
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